FY16 results on May 06, 2016
Pfizer Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 06, 2016, inter alia, to consider and take on record the Audited Financial Results of the Company for the quarter January 01, 2016 to March 31, 2016 and for the financial year ended March 31, 2016.At the said meeting, the Board of Directors will also consider recommendation of dividend, if any, for the financial year ended March 31, 2016.... Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Pfizer Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended March 31, 2016
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here Schedule of Analyst / Institutional Investor Meeting
Pfizer Ltd has informed BSE regarding "Schedule of Analyst / Institutional Investor Meeting". Pfizer Announces Termination of Proposed Combination with Allergan
Pfizer Ltd has submitted to BSE a copy of Press Release dated April 06, 2016 titled 'Pfizer Announces Termination of Proposed Combination with Allergan' Allergan, Pfizer call off proposed $160 billion merger
Pfizer Inc., will stay put thanks to aggressive new Treasury Department rules that succeeded in blocking Pfizer from acquiring rival Allergan. Intimation of Schedule of Analyst / Institutional Investor Meetings
Pfizer Ltd has informed BSE regarding "Intimation of Schedule of Analyst / Institutional Investor Meetings". Thermo Fisher Scientific in agreement with Novartis and Pfizer
To develop and commercialise a multi-marker, universal next-generation sequencing oncology test Updates
With reference to the earlier letter dated March 14, 2016 regarding Interim Injunction on the prohibition of manufacture and sale of "Corex", Pfizer Ltd has now informed BSE that the Honourable Delhi High Court at the hearing held on March 21, 2016, was pleased to extend the interim injunction suspending the operation of the Notification dated March 10, 2016, banning the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine... Pfizer India names S Sridhar as MD
A CA by profession, Sridhar has been on Pfizer India board since May 2013